Aptevo Therapeutics Inc (NASDAQ:APVO) — Market Cap & Net Worth
Market Cap & Net Worth: Aptevo Therapeutics Inc (APVO)
Aptevo Therapeutics Inc (NASDAQ:APVO) has a market capitalization of $7.68 Million ($7.68 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27482 globally and #5441 in its home market, demonstrating a 0.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aptevo Therapeutics Inc's stock price $4.92 by its total outstanding shares 1561587 (1.56 Million). Analyse cash flow conversion of Aptevo Therapeutics Inc to see how efficiently the company converts income to cash.
Aptevo Therapeutics Inc Market Cap History: 2016 to 2026
Aptevo Therapeutics Inc's market capitalization history from 2016 to 2026. Data shows change from $2.35 Billion to $7.68 Million (-50.64% CAGR).
Index Memberships
Aptevo Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #803 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2598 of 3165 |
Weight: Aptevo Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aptevo Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aptevo Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
51.19x
Aptevo Therapeutics Inc's market cap is 51.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
19.86x
Aptevo Therapeutics Inc's market cap is 19.86 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.35 Billion | $36.43 Million | -$112.42 Million | 64.42x | N/A |
| 2017 | $4.08 Billion | $14.66 Million | $6.97 Million | 278.25x | 584.91x |
| 2018 | $1.22 Billion | $23.07 Million | -$53.69 Million | 52.96x | N/A |
| 2019 | $629.59 Million | $32.42 Million | -$44.70 Million | 19.42x | N/A |
| 2020 | $2.52 Billion | $4.31 Million | -$17.75 Million | 584.41x | N/A |
| 2021 | $540.75 Million | $12.29 Million | -$27.31 Million | 43.99x | N/A |
| 2022 | $159.41 Million | $3.11 Million | $8.03 Million | 51.19x | 19.86x |
Competitor Companies of APVO by Market Capitalization
Companies near Aptevo Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Aptevo Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Aptevo Therapeutics Inc Historical Marketcap From 2016 to 2026
Between 2016 and today, Aptevo Therapeutics Inc's market cap moved from $2.35 Billion to $ 7.68 Million, with a yearly change of -50.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.68 Million | -47.83% |
| 2025 | $14.73 Million | +118.79% |
| 2024 | $6.73 Million | -45.88% |
| 2023 | $12.44 Million | -92.20% |
| 2022 | $159.41 Million | -70.52% |
| 2021 | $540.75 Million | -78.53% |
| 2020 | $2.52 Billion | +299.98% |
| 2019 | $629.59 Million | -48.46% |
| 2018 | $1.22 Billion | -70.05% |
| 2017 | $4.08 Billion | +73.77% |
| 2016 | $2.35 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Aptevo Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.68 Million USD |
| MoneyControl | $7.68 Million USD |
| MarketWatch | $7.68 Million USD |
| marketcap.company | $7.68 Million USD |
| Reuters | $7.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune … Read more